Podcasts about Recurrence

When you think about food in your breast cancer survivorship journey, what comes up for you? Panic, fear and stress, or joy, ease and peace? I want the latter of those options for you, and learning how food supports you in survivorship can help move you in that direction. Join me to hear my take on three key points in understanding post-treatment nutrition and its powerful connection to your survivorship! ____________________________Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here!Follow me on Instagram @hormone.breastcancer.dietitian

Summary In this episode of the Future of Dermatology Podcast, we share a truncated replay of Dr. Daniel Klufas's session from the SF Derm 2024 Annual Conference on the management of Hydradenitis Suppurativa (HS) with a focus on the surgical technique of deroofing. This session covers the importance of medical optimization, patient selection, and the benefits of deroofing, including low recurrence rates and high patient satisfaction. Dr. Klufas emphasizes the need for thorough preoperative planning and the role of patient expectations in surgical outcomes. Takeaways - HS was long considered a purely surgical disease. - Recent strides in medical management can delay surgical intervention. - Deroofing is a critical procedure for managing HS. - Medical optimization is essential before considering surgery. - Patients should be well-informed about their treatment options. - Deroofing can be performed on solitary or regional lesions. - Patient satisfaction rates for deroofing are high. - Recurrence rates for deroofing are generally low. - Preoperative planning is crucial for successful outcomes. - Pain management post-deroofing is often less than expected. Chapters 00:00 - Introduction to the Future of Dermatology Podcast 01:00 - Understanding Hydradenitis Suppurativa (HS) and Surgical Management 03:14 - Medical Optimization and Patient Selection for Deroofing 05:01 - Deroofing Technique and Surgical Pearls 08:15 - Patient Satisfaction and Outcomes of Deroofing

Our final breast cancer episode is here! Today, we are talking about the role of Gene Expression Assays in early hormone receptor-positive breast cancer management. The specific questions we asked included when we can de-escalate and for which cohort of patients these assays can be used. There's lots more to this episode, but we explore the role of Oncotype Dx!Studies discussed in the episode:TAILORxRxPonderFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Dr. Kristi Funk reveals the power you hold to transform your health and prevent breast cancer in just two weeks! Learn how a whole food plant-based diet and exercise can drastically change your blood into a cancer-kicking machine. Dive into the eye-opening study on the Pricin Plan and discover how simple lifestyle changes can significantly lower your breast cancer risk. #BreastCancerAwareness #HealthyLiving #PlantBasedDiet

A fantastic episode for urologists, radiation oncologists, and anyone interested in localised prostate cancer. Biochemical recurrence (BCR) is unfortunately all too common after surgery or radiation for prostate cancer, and today we talk with someone who has been working in BCR for more than 20 years. Dr Steve Freedland, Urologist at Cedars-Sinai in Los Angeles, popped into the GU Cast studio to talk about the landmark series from Johns-Hopkins Medical Institute (links below) which still today remains our best guide to the natural history of BCR after radical prostatectomy. And the key message that PSA doubling time is our most important tool to risk stratify patients reminds true today. And Steve of course is the lead investigator of the EMBARK trial, published in NEJM in 2023, which has led to a new standard of care for men experiencing high-risk BCR after surgery or radiotherapy. EMBARK has clearly shown us that the use of enzaluamide, either on its own, or with androgen deprivation therapy, reduces the risk of metastases when compared with ADT alone. We dive deep into EMBARK with Steve.This is a Themed Podcast supported by our Gold Partners, Astellas. Astellas also supported Steve to be in Australia this week for the USANZ ASM in Perth, and visits to Melbourne and Sydney. Your hosts are Professor Declan Murphy and Dr Renu Eapen. Even better on our Youtube channelLinks:Freedland et al JAMA 2005 EMBARK paper in NEJM

Metastatic Triple Negative Breast Cancer is one of the most challenging breast cancer subtypes to treat. Recurrence rates can be as high as 40%. This episode covers the role of immunotherapy and antibody-drug conjugates in the advanced space. Once again, targetable receptors are lacking but research is underway!Studies discussed in the episode:KEYNOTE 355ASCENTFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

How does lymph node assessment play a pivotal role in personalized, multidisciplinary care? Credit available for this activity expires: 2/24/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002279?ecd=bdc_podcast_libsyn_mscpedu

Prevention of breast cancer recurrence is the holy grail, but how much do you know about eating in a way that makes that a reality? It's possible you've been fed inaccurate facts and myths, so Cathy clarifies what eating for prevention looks like and shares two suggestions for a sane, lifelong approach to eating to manage risk. ___________________________ Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here! Follow me on Instagram @hormone.breastcancer.dietitian

March 2025 Journal Club Podcast Title: Gene Expression Changes Associated With Recurrence After Gross Total Resection of Newly Diagnosed World Health Organization Grade 1 Meningioma To read journal article: https://journals.lww.com/neurosurgery/fulltext/2025/03000/gene_expression_changes_associated_with_recurrence.6.aspx Author: Ramin Morshed Guest Faculty: Tomas Garzon-Muvdi Moderator: Kimberly Hoang Resident Planner: Alexander Himstead

Send us a textConfronting the Fear of Cancer RecurrenceWelcome to the latest Series of Supportive Care Matters, a podcast hosted by Medical Oncologist and International Cancer Survivorship Expert, Professor Bogda Koczwara AM.The fear of cancer returning is a silent struggle for many survivors, often overshadowing their recovery. In Episode 1 of this new Series, Bogda explores this deep-seated anxiety with experts Professor Sophie Lebel and Associate Professor Ben Smith.They unpack the realities of recurrence fears — why they persist, who is most affected and how they impact daily life. Research shows nearly every cancer survivor experiences some level of worry, but for 40%, it becomes a significant source of distress. Caregivers, too, often share in this burden.Sophie and Ben highlight the need for better interventions, especially for underrepresented groups, and share practical strategies for managing fear in clinical settings. From open conversations to structured support pathways, they highlight ways to help survivors move forward with confidence.Join us for an insightful discussion on breaking the cycle of fear and fostering a more supportive, hopeful survivorship journey.Visit www.oncologynews.com.au for show notes and more information about Supportive Care Matters.This conversation is proudly produced by the Podcast Team at The Oncology Podcast, part of the Oncology Media Group Australia.

Quick apology...My mic wasn't turned on, but at least Samantha sounds great! In this conversation, Jen and Samantha Harris discuss the journey of breast cancer, reflecting on Samantha's initial diagnosis, the challenges of treatment, and the emotional aftermath. They emphasize the importance of self-advocacy, understanding one's body, and the role of lifestyle changes in managing health. The conversation also touches on the recurrence of cancer and the empowerment that comes from knowledge and support systems. Takeaways Samantha reflects on the changes in her life since her last interview. The importance of being proactive in health advocacy is highlighted. The significance of knowing one's body and recognizing changes is emphasized. Samantha discusses the recurrence of her cancer and the fear associated with it. The conversation stresses the need for a supportive medical team. Lifestyle changes play a crucial role in health management post-diagnosis. Samantha shares her approach to navigating treatment options. You can connect with Samantha here: https://samantha-harris.com Samantha Harris Instagram: https://www.instagram.com/samanthaharristv/ RESOURCES & LINKS Midi Health: Take control of your hormonal health with personalized testing and plans. Check out the survivrship program here Non-Toxic Product Recommendations: https://www.jendelvaux.com/Non-toxic-Recommendations CACAO Adaptogen with 4 functional mushrooms. Use HELLO10 for $10 off The BLUEPRINT from Results to Rising details HERE FREE Download of cancer fighting vegan recipes: HERE Connect with me on Instagram: https://www.instagram.com/jendelvaux/ EMAIL ME: coachjennyd@gmail.com FAVORITE TEA: Pique Tea:  https://www.piquetea.com/?rfsn=5818415.d1d969a&utm_source=affiliate

Disclaimer: This podcast does not provide medical advice. The content of this podcast is provided for informational or educational purposes only. It is not intended to be a substitute for informed medical advice or care. You should not use this information to diagnose or treat any health issue without consulting your doctor. Always seek medical advice before making any lifestyle changes. Amber Orman, MD, DipABLM is a double board-certified radiation oncologist and lifestyle medicine specialist focusing on breast cancer treatment and prevention, providing holistic care that encompasses mind and body. She joined AdventHealth from Moffitt Cancer Center and the University of South Florida Morsani School of Medicine in Tampa, where she served as staff and medical faculty, respectively. She is the first ever Chief Wellness Office (CWO) of AdventHealth Medical Group, working to improve the well-being of her colleagues. She is also the co-founder of the HEAL (Healthy Eating and Active Lifestyle) program at AdventHealth in Orlando, Florida. HEAL is an 8-week lifestyle medicine program designed to educate and inspire cancer patients to make positive changes to decrease cancer recurrence and improve overall healthspan. She collaborates with the American College of Lifestyle Medicine as a member of the Health Systems Council and was a past Chair of the Cancer Member Interest Group. She is the Medical Director of AdventHealth Lifestyle Ventures as well as an Assistant Professor at the University of Central Florida College of Medicine. Her research interests include integrative therapies and their applications to cancer prevention, treatment and survivorship, with a strong emphasis on nutrition.

Send us a textDiscover the hidden complexities behind perineal hernia recurrence in dogs as we chat with Dr. Mandy Wallace and Abigail Hatch. Mandy and Abigail provide fascinating insights into the risks associated with hernia development and the challenges of fecal incontinence. Mandy and Abigail emphasize the crucial need for pet owner education. Their discussion offers a deep dive into the nuances of soft tissue surgery, contrasting it with the generally healthier cases found in orthopedic surgery, while sharing personal journeys that led them to this specialized field.Our conversation also touches on the evolution of veterinary record-keeping, highlighting the shift from paper to electronic systems and how this impacts data collection for retrospective studies. Mandy and Abigail offer their perspectives on improving these practices, guided by their own experiences with scientific writing and mentorship. This episode promises a blend of serious insights and light-hearted moments with two passionate professionals in the veterinary world.JAVMA article: https://doi.org/10.2460/javma.24.07.0487INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Louie Helmecki shares his deeply personal journey through multiple cancer diagnoses, shedding light on the emotional, physical, and medical challenges he faced along the way. From enduring chemotherapy and surgeries to navigating the complexities of cancer recurrence, Louie speaks candidly about the toll of treatment and the resilience required to push forward. He and Freddie Kimmel discuss the critical role of health ownership, the importance of advocating for the right medical care, and the gaps in traditional medicine that often leave patients searching for more holistic solutions. Louie's story is not just about surviving but about reclaiming control over his well-being and redefining what it means to thrive beyond cancer. This conversation also delves into groundbreaking health innovations, including the use of peptides, GLP-1 medications, and lifestyle medicine as tools for recovery and disease prevention. Freddie and Louie explore the latest advancements in cancer detection, weight management, and muscle preservation, emphasizing the importance of a personalized and proactive approach to health. They highlight the growing integration of complementary therapies like red light therapy, IV treatments, and biohacking strategies that support the body's natural healing process. More than just a story of struggle, this episode is a testament to the power of mindset, education, and taking action to build a life beyond illness.Chapters00:00 Introduction to Cancer Journeys05:00 Louie's Cancer Diagnosis and Initial Treatment09:52 Chemotherapy Experiences and Challenges16:01 Surgery and Recovery Insights20:01 Recurrence and New Diagnosis30:00 Navigating Medical Decisions and Expert Opinions35:50 Navigating Cancer Treatment Experiences41:07 The Intersection of Traditional and Complementary Medicine49:01 Innovations in Health and Wellness Practices55:46 Understanding Peptides and Their Impact on Health01:05:59 Exploring Weight Loss Medications01:08:02 The Importance of Comprehensive Health Assessments01:09:55 Navigating Weight Loss Programs Responsibly01:12:03 Innovative Approaches to Health and Wellness01:16:52 Cancer Detection and Preventative Measures01:26:51 Life Lessons from Cancer SurvivalUPGRADE YOUR WELLNESSSilver Biotics Wound Healing Gel: https://bit.ly/3JnxyDD (30% off)Code: BEAUTIFULLYBROKENSaga Bands: https://ca.saga.fitness/?ref=titvyccmCode: beautifullybrokenStemRegen: https://www.stemregen.co/products/stemregen?_ef_transaction_id=&oid=1&affid=52Code: beautifullybrokenLightPathLED https://lightpathled.pxf.io/c/3438432/2059835/25794Code: beautifullybroken CONNECT WITH FREDDIE Check out my website and store: (http://www.beautifullybroken.world) Instagram: (https://www.instagram.com/beautifullybroken.world/) YouTube: (https://www.youtube.com/@BeautifullyBrokenWorld)

Discover the hidden factors behind the rising breast cancer rates as Dr. Kristi Funk dives deep into the impact of lifestyle and diet. Learn how Asian immigrants in the US experienced a 100% increase in breast cancer rates due to Western lifestyle changes and how you can take control to reduce your risk. Join Dr. Funk as she reveals the powerful influence of nutrition on your health. #BreastCancerPrevention #HealthyLiving #NutritionMatters

In this JCO PO Article Insights episode, Harold Nathan Tan summarizes findings from the JCO PO article, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights where we explore cutting-edge discoveries in the world of cancer treatment and research. I'm Harold Nathan Tan, your host for today's episode. Let's dive into a fascinating study published in JCO Precision Oncology entitled, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” This study led by Dr. Eric Michael Lander and colleagues examines a critical question: Can circulating tumor DNA help predict recurrence in patients with esophagogastric cancer who have achieved a favorable pathologic response after treatment? Esophagogastric cancer ranks as the seventh leading cause of cancer-related deaths worldwide. Despite aggressive treatment including neoadjuvant therapy followed by surgery, recurrence remains a grim reality for many patients. Interestingly, even those who achieve a pathologic complete response face a recurrence risk of up to 25%. This highlights a need for better tools to identify high-risk patients post-treatment. Circulating tumor DNA, or ctDNA for short, is emerging as a powerful biomarker in oncology. This minimally invasive blood-based test detects fragments of tumor DNA in the bloodstream, potentially signaling molecular residual disease before any radiographic evidence of recurrence appears. In this study, researchers focused on patients with locoregional esophagogastric cancer who had undergone neoadjuvant therapy followed by surgery, achieving either a complete or near complete pathologic response. Blood samples were collected postoperatively within a 16-week molecular residual disease window and during routine surveillance. The aim is to determine whether ctDNA positivity correlates with recurrence-free survival. The study analyzed 309 plasma samples from 42 patients across 11 institutions. Detectable ctDNA within the 16-week postoperative window was associated with a significantly higher recurrence risk. Among those with detectable ctDNA, 67% experienced recurrence compared to only 15% for those with undetectable ctDNA. This corresponds to a hazard ratio of 6.2, an alarming figure that underscores the potential for ctDNA as a prognostic tool. But the story doesn't end there. Postoperative surveillance ctDNA testing more than 16 weeks after surgery also proved to be a powerful prognostic indicator. Every patient with detectable ctDNA during surveillance eventually experienced recurrence, while only 7.4% of those with undetectable ctDNA relapse. These findings suggest that ctDNA testing could provide a critical lead time, enabling earlier interventions and personalized treatment strategies. Now let's talk about the clinical implications. Currently, patients who achieve a pathologic complete response often aren't considered for adjuvant therapies as the absence of visible disease is taken as a sign of remission. However, this study challenges that assumption. By integrating ctDNA testing into routine post-treatment surveillance, clinicians could identify high-risk patients who might benefit from additional therapy even when traditional imaging shows no signs of recurrence. This brings us to the bigger picture. Esophagogastric cancer treatment is evolving rapidly, with trials like CheckMate 577 and ESOPEC offering new insights into perioperative strategies. However, this study highlights a critical gap, the need for personalized, biomarker-driven approaches in the adjuvant setting. ctDNA could fill that gap, offering a non-invasive, dynamic way to monitor patients and guide clinical decisions. Of course, no study is without its limitations. The authors acknowledge the relatively small sample size and the retrospective nature of their analysis. They also note the variability in ctDNA testing and imaging schedules across institutions. However, the robust association between ctDNA positivity and recurrence-free survival makes a compelling case for further research in larger prospective cohorts. Looking ahead, what's the next step? The authors call for prospective validation of ctDNA as a prognostic tool, emphasizing its potential to refine risk stratification and optimize treatment strategies. Imagine a future where a simple blood test could dictate not only the need for additional therapies, but also the timing and type of intervention. As we wrap up, let's reflect on the broader impact of the study. By integrating ctDNA into routine cancer care, we could move closer to a world where treatments are not just effective, but also precisely tailored to each patient's unique biology and disease dynamics. Thank you for tuning into JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. Until then, stay informed and stay inspired.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

So many women finish treatment for hormone-driven breast cancer and struggle to navigate their alcohol consumption; it causes so much angst! In today's episode I highlight the connection between alcohol and recurrence risk and guide you through an exercise in decision-making about your own approach to alcohol. If you feel guilty about your nightly wine or weekend martini habit, this is the episode for you!  Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here! Follow me on Instagram @hormone.breastcancer.dietitian

Episode Highlights: Happy New Year from Molly and Clarissa!

What are the risk factors and frequency of recurrence in patients with acute anterior uveitis? Dr. Edmund Tsui and Dr. Rachael L. Niederer delve into the findings of her recent Ophthalmology study, “Risk of Recurrence in Acute Anterior Uveitis.” Risk of Recurrence in Acute Anterior Uveitis. Brodie, James T. et al. Ophthalmology, Volume 131, Issue 11, 1281 – 1289.

Dr. Kristi Funk shares powerful insights on breast cancer, emphasizing how much control you have over this disease. Discover crucial statistics, risk factors, and preventative measures you can take today to reduce your risk. Learn how to take charge of your health and make informed decisions. Watch now to feel empowered and incentivized to protect yourself against breast cancer. #BreastCancerAwareness #PreventBreastCancer #DrKristiFunk

Have you checked out the AUA/ASTRO/SUO's recently released guidelines for salvage therapy in prostate cancer biochemical recurrence? In this episode of the BackTable Urology Podcast, guest Dr. Todd Morgan from the University of Michigan and host Dr. Aditya Bagrodia continue with part two of our series on prostate cancer biochemical recurrence management. --- This podcast is supported by: Veracyte https://www.veracyte.com/decipher --- SYNPOSIS The doctors focus on the difficulty in declaring a patient 'cured' and the implications of biochemical recurrence after treatment. Dr. Morgan highlights the importance of PSA in the postoperative setting and explores the role of the Decipher Prostate Genomic Classifier in personalizing treatment. He talks through the latest AUA/ASTRO/SUO consensus on biochemical recurrence guidelines, including the significance of early salvage therapy and the integration of advanced imaging techniques like PSMA PET scans. Further, Dr. Morgan emphasizes the role for multidisciplinary evaluation, patient counseling, and future directions of research to refine treatment options. This discussion underscores the transition from adjuvant to early salvage radiation as a standard practice and considers emerging biomarker strategies to inform treatment decisions. --- TIMESTAMPS 00:00 - Introduction 03:41 - Consensus Biochemical Recurrence Guidelines 08:56 - Evolution of Post-Prostatectomy Biochemical Recurrence Management 13:24 - Patient Counseling and Risk of Recurrence 17:42 - PSMA PET Scans 20:44 - Postoperative PSA Monitoring 28:35 - The Role of Radiation 31:56 - Hormone Therapy 39:00 - Salvage Lymphadenectomy 46:30 - Future Directions and Concluding Thoughts --- RESOURCES Veracyte https://www.veracyte.com/ Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline (2024) https://www.auanet.org/guidelines-and-quality/guidelines/salvage-therapy-for-prostate-cancer

Stay up to date in your bladder cancer practice with this insightful episode of the BackTable Urology podcast, developed in collaboration with the Society of Urologic Oncology. Dr. Betsy Koehne (University of Wisconsin) and Dr. Amir Salmasi (UC San Diego) talk through the contemporary management of low and intermediate-risk non-muscle-invasive bladder cancer. --- SYNPOSIS The doctors explore the challenges and nuances of patient communication, intravesical therapy, and postoperative surveillance. They also cover emerging treatments and clinical trials that hold promise for improving patient outcomes and quality of life. Emphasis is placed on the distress experienced by patients and the need for personalized treatments. --- TIMESTAMPS 00:00 - Introduction 01:51 - Initial Consultation 08:01 - TURBT Procedure Insights 23:14 - Managing Low and Intermediate Risk Bladder Cancer 26:47 - Recurrence and Surveillance Strategies 27:48 - Prognostication Tools 30:10 - Intravesical Chemotherapy Options 33:24 - High Grade Tumors 42:33 - Clinical Trials and Emerging Therapies 49:19 - Concluding Thoughts

In this episode of the Better Edge podcast, Bruce K. Tan, MD, associate professor of Otolaryngology – Head and Neck Surgery at Northwestern Medicine, discusses his recent research study titled, “Increased Autoreactivity and Maturity of EBI2+ Antibody-Secreting Cells from Nasal Polyps,” which sheds light on the cells' role in predicting polyp recurrence after sinus surgery and the potential implications for diagnosing and treating nasal polyps. The findings also contribute to our understanding of immune response, antibodies and inflammation in respiratory conditions, highlighting the unique activation mechanisms and tissue-resident memory cells in the airway.

TODAY ON THE ROBERT SCOTT BELL SHOW: Unhealthy Diet Diseases, Dr. Robert Bard, Cancer recurrence prevention, Aloe Socotrina, CDC Hyper-Vaccination Agenda, Hava Levi & Nicole Dromy, Herbal Healing, Vitamin D3 Rat Poison, Babies' Werewolf Syndrome and MORE! https://robertscottbell.com/unhealthy-diet-diseases-dr-robert-bard-cancer-recurrence-prevention-aloe-socotrina-cdc-hyper-vaccination-agenda-hava-levi-nicole-dromy-herbal-healing-vitamin-d3-rat-poison-babies-w/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

Smart Choices to Lower Breast Cancer Recurrence Risk with Dr. Eleonora TeplinskyHow the impacts of exercise, sugar & alcohol affect your risk + how supplements and certain foods affect risk and recurrence.Is your lifestyle supporting your health, or could small changes make a big impact when it comes to breast cancer?What if you could lower your breast cancer risk with simple adjustments to your nutrition and daily habits?Ready to uncover the simple yet powerful steps you can take to improve your survivorship and support your recovery?In this EXTENDED SPECIAL COMPILATION EPISODE taken from the best parts of three separate interviews with Dr. Teplinsky, you will uncover the latest research and tips to reduce your risk and recurrence.Tune in to discover choices that can make a world of difference for your health future, as Dr. Eleonora Teplinsky shares her expert insights on preventing cancer and boosting wellness!In this episode, you will learn:The role of nutrition in breast cancer prevention and survivorshipHow plant-based diets can help reduce breast cancer riskThe importance of limiting processed foods and increasing plant-based optionsVitamin D's crucial role for breast cancer survivorsVitamin D2 vs. D3: Which is one should I take and why.Soy - not what you thought & the role of soy in a breast cancerHelpful supplements and which to avoidHow outdoor sun exposure plays a crucial role for your vitamin DTamoxifen's effect on cholesterol and managing heart healthAnastrozole and certain foods or spicesZolidex and the need or not for a "multiplier"Alcohol and sugar's impact on breast cancer recurrenceLatest studies on sugar -- the truths you may not want to know but shouldMeat consumption and cancer riskBalanced, plant-based diet breakdown for heart and breast healthDr. Teplinsky's approach to personalized prevention plansSelf-exams and breast health guidelines that you must know now!Abnormal findings and what shouldn't be ignoredThe emotional challenge of discovering a lumpShould you seek out a second opinions for your cancer careHow to advocate for yourself during medical appointmentsSmall but essential lifestyle edits for reducing your breast cancer riskExercise and cancer recurrenceWhich nutrition choices can lower cancer riskHealthier alcohol choices to reduce cancer riskWhat toxins in your daily life need to be reduced and how to do itThe ongoing debate over dairy and cancer... And much moreGUEST EXPERT:DR. ELEONORA TEPLINSKYBreast & GYN Oncologist / Host of the podcast "Interludes"ABOUT :Dr. Teplinsky is a board-certified medical oncologist specializing in breast and gynecologic oncology. She is the the Head of Breast Medical Oncology at Valley-Mount Sinai Comprehensive Cancer Care in Paramus, NJ and a Clinical Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York.She started the INTERLUDE podcast as a way to share the stories of women who have been affected with cancer as a way to provide support, inspiration, encouragement, hope and strength to other women who are also going through similar experiences.MORE ON DR. TEPLINSKY:

Biochemical recurrence of prostate cancer can be difficult to diagnose and treat. In this episode of BackTable Urology, where Dr. Aditya Bagrodia hosts Dr. Amar Kishan, a genitourinary radiation oncologist at UCLA, to discuss the complexities of biochemical recurrence and local failure after radiation therapy for prostate cancer. --- This podcast is supported by: Veracyte https://www.veracyte.com/decipher --- SYNPOSIS First, they evaluate alternatives to androgen deprivation therapy (ADT), the benefits and risks associated with ADT, and the role of genetic classifier tests. They also detail the goals of prostate-specific antigen (PSA) monitoring, PSA trends post-radiation, and advancements in PSMA PET scans. Then, the conversation highlights modern treatment options like targeted radiation, low dose rate brachytherapy, salvage radical prostatectomy, and focal therapy. Finally, the doctors emphasize personalized and multidisciplinary treatment plans as they hope to improve long-term outcomes for patients with prostate cancer. --- TIMESTAMPS 00:00 - Introduction 04:31 - PSA Levels Post-Radiation 13:21 - Local Recurrence and PSMA PET 21:29 - Explaining Radiation Effects to Patients 22:41 - Managing PSA Bounce 26:05 - Imaging and Biopsy Techniques 28:55 - Treatment Options for Local Recurrence 30:16 - Re-Irradiation and Focal Therapy 33:13 - Concluding Thoughts --- RESOURCES Veracyte https://www.veracyte.com/

On today's episode, we are discussing a topic that affects most women with hormone receptor-positive, early-stage breast cancer after they finish their initial treatment and begin navigating survivorship. To lower the risk of recurrence, most women begin taking anti-estrogen therapy, also called hormone therapy or endocrine therapy, but these treatments do not come without the risk of side effects. When side effects become severe, survivors may be faced with the task of weighing the benefits of hormone therapy against the associated side effects. This can be challenging and may even lead them to wonder how much longer they need to continue on the medication. Joining us today to discuss how patients and providers can balance fear of recurrence against potential side effects of treatment and how genomic testing can help guide treatment decisions is a Nurse Practitioner at Memorial Sloan-Kettering Cancer Center, Adriana Olivo. This podcast is sponsored by Biotheranostics Inc., a Hologic Company. The Breast Cancer Index test is the only test recognized by the NCCN guidelines and the ASCO Clinical Practice Guideline to predict which patients are likely to benefit from extension of adjuvant anti-estrogen therapy beyond 5 years.

Cancer dormancy is a phenomenon in which, after treatment, residual cancer cells remain inactive in the body for months or even years. During this time, patients often show no signs of the disease. These dormant cells can unpredictably reawaken, leading to tumor recurrence—a significant challenge in cancer treatment. Despite progress in cancer research, the factors that control dormancy and subsequent reactivation remain poorly understood. Identifying these factors and understanding how cancer cells dormancy and reactivation occur could be crucial to preventing cancer recurrence. This question was the focus of a recent study titled “Initiation of Tumor Dormancy by the Lymphovascular Embolus,” published in Oncotarget Volume 15, on October 11, 2024. In this blog, we will look at the key findings and implications of this important work. Full blog - https://www.oncotarget.org/2024/11/13/cancer-dormancy-and-tumor-recurrence-new-insights-for-breast-cancer/ Research paper DOI - https://doi.org/10.18632/oncotarget.28658 Correspondence to - Sanford H. Barsky - sbarsky@mmc.edu Video short - https://www.youtube.com/watch?v=z6ex7Yl8r5Q Sign up for free Altmetric alerts about this article: https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28658 Subscribe for free publication alerts from Oncotarget: https://www.oncotarget.com/subscribe/ Keywords - cancer, dormancy, lymphovascular embolus, mTOR, E-cadherin proteolysis About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

I know you're looking for the “best” diet to eat after finishing treatment, and it can be frustrating when you can't find the exact food to eat that will make you less panicked about your nutrition. In today's episode I share why you can't find the diet you're looking for, and teach you three science-backed diet changes that absolutely support your breast and overall best health. Grab your notebook and join me for this information-packed episode! Click here to apply to my Peaceful Plate program! Get my FREE guide The Five Foods Survivors Should Eat; click here! Follow me on Instagram @hormone.breastcancer.dietitian

Dr. Amy Rothenberg, a respected naturopathic physician and three-time cancer survivor, shares her story of multiple cancer diagnoses and treatments. Her most recent treatment was a stem cell transplant in 2024 for acute leukemia. Dr. Rothenberg gives valuable insights into integrative cancer care, the importance of gut health, and practical tips for caregivers. The conversation also emphasizes the significance of maintaining a healthy lifestyle and seeking open-minded, collaborative healthcare providers. Tune in for an informative and inspiring discussion on navigating cancer care holistically.Link to Dr. Rothenberg's social media and websiteBe The Match Program - Becoming a stem cell donorWhat is a Stem Cell Transplant? NIH explanationTips for Caregivers of Patients — a guest blog post by Dr. RothenbergUnderstanding Cancer-Related FatiguePrevious podcast episodes :Dr. Amy Rothenberg's initial interview with usCancer-Related FatiguePrebiotics (Microbiome stuff)Chemotherapy-Induced NeuropathySupport the showOur website:https://www.thecancerpod.com Email us: thecancerpod@gmail.comJoin our growing community! We are @TheCancerPod on: Instagram Twitter Facebook LinkedIn THANK YOU for listening!

Get a second opinion on your uterine fibroid embolization (UFE) technique. Dr. Gary Siskin joins host Dr. Chris Beck for an in-depth discussion on his approach to uterine fibroid embolization, detailing techniques, tools, and embolic agents. Dr. Siskin is an experienced UFE practitioner, professor, and Chair of the Department of Radiology and Chief of the Division of Vascular & Interventional Radiology at Albany Med Health System in New York. --- This podcast is supported by: Merit Embolotherapy https://www.merit.com/solutions/embolotherapy/ --- SYNPOSIS Dr. Siskin shares his journey and evolution of his specialization in GYN-related interventional radiology procedures. The doctors cover various aspects of fibroid embolization, including its effectiveness compared to surgical options like myomectomy and hysterectomy, the referral and evaluation process, and considerations for fertility preservation. Pain management strategies and postoperative care are also explored, emphasizing the importance of patient education and interdisciplinary collaboration to promote less invasive treatments. --- TIMESTAMPS 00:00 - Introduction 04:45 - Building a Fibroid Practice 08:35 - Workup and Consultation 17:01 - Recurrence and Re-Embolization 20:27 - Pre-Procedural Workup and Technique 30:18 - Embolization Endpoint 36:07 - Accessing the Correct Uterine Artery 48:49 - Post-Procedure Patient Care --- RESOURCES List of Publications by Dr. James B. Spies (PubMed): https://pubmed.ncbi.nlm.nih.gov/?sort=jour&term=Spies+JB&cauthor_id=24436560

In this episode, Dr. Lily Wang, a neuroradiologist at the University of Cincinnati, discusses the critical role of imaging in monitoring patients after thyroidectomy for differentiated thyroid cancer (DTC). Differentiated Thyroid Cancer after Thyroidectomy. Chua et al. RadioGraphics 2024; 44(10):e240021.

Following an emergency c-section due to HELLP syndrome in her first pregnancy, Jolene Brink was determined to have a different birthing experience with her second child. Through the support of a knowledgeable medical team and insights gained from her EBB Childbirth Class, she successfully achieved her goal of an unmedicated VBAC with the birth of her son, Guthrie, in 2022. Jolene's journey towards a VBAC was a transformative process of healing, empowerment, and reclaiming her birthing experience, showcasing the importance of advocacy and informed decision-making in maternal healthcare. Resources: Check out Doulas of Duluth to learn from her instructors Cooper Orth and Dana Morrison, and follow them on Instagram! Learn about Jolene's work here! Read The Preeclampsia Foundation's article on HELLP Syndrome Follow the Preeclampsia Foundation on Instagram van Oostwaard, M. F. et al. (2015). "Recurrence of hypertensive disorders of pregnancy: An individual patient data meta-analysis." Am J Obstet Gynecol 212(5): 624.e1-17. https://pubmed.ncbi.nlm.nih.gov/25582098/ Duley, L., et al. (2019). "Antiplatelet agents for preventing pre-eclampsia and its complications." Cochrane Database Syst Rev. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820858/ Listen to the Evidence on VBAC - EBB 113 EBB Childbirth Class now includes a module all about planning a VBAC! Learn more about the EBB Childbirth class here. For more information about Evidence Based Birth and a crash course on evidence based care, visit www.ebbirth.com. Follow us on Instagram, YouTube, and TikTok! Ready to learn more? Grab an EBB Podcast Listening Guide or read Dr. Dekker's book, "Babies Are Not Pizzas: They're Born, Not Delivered!" If you want to get involved at EBB, join our Professional membership (scholarship options available) and get on the wait list for our EBB Instructor program. Find an EBB Instructor here, and click here to learn more about the EBB Childbirth Class.

We've talked a lot about the benefits of probiotics on this channel! But did you know how effective probiotics are for women's health? We've compiled some of our most surprising insights into women's health and probiotics into this one episode. Learn more, watch now!  Curious about the other benefits of probiotics? Check out these videos!